Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) said its executive team will take part in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 AM EST.
A webcast will be available via the company’s Investors site after the conference. The summit runs February 11-12, 2026 in New York City.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
In the Feb 4 session, AKBA declined 2.84%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-01-12 | Corporate update | Positive | -7.9% | Outlined Vafseo progress, VOICE/VOCAL timelines, and 2026 pipeline plans. |
| 2026-01-06 | Clinical trial start | Positive | -2.6% | First patient dosed in Phase 2 praliciguat trial for FSGS. |
| 2026-01-05 | Inducement grants | Neutral | -2.6% | Inducement stock options granted to a new employee under Nasdaq rules. |
| 2025-12-01 | Inducement grants | Neutral | -2.6% | Stock options granted to new hires under inducement award program. |
| 2025-12-01 | Pipeline expansion | Positive | -4.4% | Announced establishment of rare kidney disease pipeline with AKB‑097 and praliciguat. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive pipeline and corporate updates have been followed by negative share reactions, suggesting a pattern of selling into good news.
Over the last few months, Akebia has focused on expanding its kidney disease pipeline and advancing key programs. On Dec 1, 2025, it established a rare kidney disease pipeline around AKB‑097 and praliciguat. A corporate update on Jan 12, 2026 highlighted Vafseo progress, Phase IV VOICE enrollment (> 2,100 patients), and VOCAL enrollment (~350 patients) with revenue expectations of $5–$6 million for Q4 2025. Despite these developments, shares declined after several of these announcements, contrasting with the neutral nature of today’s conference participation news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
The Emerging Outlook: Biotech Summit hosted by Guggenheim Securities, LLC, will take place February 11-12, in New York City.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
